Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of YTS109 Cell for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy

NCT07075484 is registered in ClinicalTrials.gov with China Immunotech (Beijing) Biotechnology Co., Ltd. as lead sponsor.

NCT NCT07075484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07075484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of YTS109 Cell for Relapsed/Refractory Autoimmune Hemolytic Anemia Patients After Receiving Three or More Lines of Therapy
Lead sponsor
China Immunotech (Beijing) Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
January 15, 2025
Completion date
February 27, 2026
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune hemolytic anemia